Premium
Sulphydryl group control of sodium‐lithium countertransport kinetics: a membrane protein control abnormality in essential hypertension
Author(s) -
THOMAS T. H.,
RUTHERFORD P. A.,
WEST I. C.,
WILKINSON R.
Publication year - 1995
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1995.tb01554.x
Subject(s) - sodium , extracellular , lithium (medication) , chemistry , intracellular , essential hypertension , endocrinology , medicine , extracellular fluid , biochemistry , biology , blood pressure , organic chemistry
. Erythrocyte sodium‐lithium countertransport (SLC) is an obligatorily coupled equimolar exchange of intracellular sodium or lithium with extracellular sodium or lithium. SLC is partially inhibited by N‐ethylmaleimide (NEM) but only when a transported ion (sodium or lithium) is present in the extracellular medium. In essential hypertensive patients with a strong family history of hypertension the Km of SLC for extracellular sodium was lower and Vmax tended to be higher than in normal controls, but the ratio Vmax/ Km gave a much clearer distinction between the two groups. After NEM treatment, the remaining SLC activity in normal individuals had a lower Vmax and Km for sodium but Vmax/Km was not affected. In essential hypertensives the remaining SLC activity after NEM again had lowered Vmax and Km but in these patients the Vmax/Km was much lower than in untreated erythrocytes and was then the same as in normal controls. On the assumption that NEM reacts with a ‐SH group on a membrane protein that regulates SLC, and that the ratio Vmax/Km reflects a rate constant for binding extracellular sodium to the unloaded carrier, the results suggest that (a) essential hypertensives have an increased rate of sodium binding to the transporter and (b) this is due to abnormal behaviour of a membrane ‐SH group.